Form 4: Avidity Biosciences CFO Acquires Shares and Stock Options

Avidity Biosciences' Chief Financial Officer, Michael F. MacLean, acquired 25,000 restricted stock units and 50,000 stock options on January 6, 2025.

Summary

• Michael F. MacLean, the Chief Financial Officer of Avidity Biosciences, acquired 25,000 restricted stock units (RSUs) and 50,000 stock options on January 6, 2025.
• The RSUs vest in four equal installments on the first four anniversaries of January 6, 2025, contingent on continuous service.
• The stock options vest in 48 equal monthly installments from the grant date, fully vesting on January 6, 2029.
• The exercise price of the stock options is $31.42.
• Following these transactions, Mr. MacLean directly owns 107,942 shares of common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine insider transaction, which is generally positive as it shows management's alignment with the company's success. There is no indication of any negative sentiment.

Positives

• The acquisition of shares and options by the CFO demonstrates confidence in the company's future.
• The vesting schedules for both RSUs and options align with long-term value creation.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of compensation for executives in the biotechnology industry, aligning their interests with shareholders.
• The vesting schedules described are typical for such grants, designed to incentivize long-term performance and retention.
• The exercise price of $31.42 for the stock options is a standard practice, often set at or above the market price at the time of grant.

Stakeholder Impact

• The transaction may have a slightly positive impact on shareholder sentiment, as it indicates management's confidence in the company.

Key Dates

Keywords

Avidity Biosciences, CFO, Michael F. MacLean, stock options, restricted stock units, RSUs, insider trading, share acquisition, vesting